Federated Hermes Inc. Sells 174,992 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Federated Hermes Inc. trimmed its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 34.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 326,058 shares of the company's stock after selling 174,992 shares during the period. Federated Hermes Inc. owned approximately 0.26% of Vaxcyte worth $26,691,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of PCVX. Whipplewood Advisors LLC purchased a new position in shares of Vaxcyte in the 4th quarter worth about $28,000. Smartleaf Asset Management LLC lifted its position in Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the last quarter. National Bank of Canada FI purchased a new stake in Vaxcyte in the fourth quarter worth approximately $41,000. Blue Trust Inc. grew its position in Vaxcyte by 100.0% during the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after acquiring an additional 371 shares during the last quarter. Finally, Assetmark Inc. grew its position in Vaxcyte by 77,500.0% during the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after acquiring an additional 775 shares during the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on PCVX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Bank of America decreased their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. The Goldman Sachs Group dropped their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Guggenheim restated a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a research report on Wednesday, March 12th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $136.50.

Remove Ads

Vaxcyte Stock Up 1.6 %

Shares of PCVX traded up $0.49 during mid-day trading on Monday, hitting $31.69. 379,341 shares of the company's stock traded hands, compared to its average volume of 1,194,426. The firm has a market capitalization of $4.08 billion, a P/E ratio of -6.89 and a beta of 1.26. The business's 50-day moving average price is $66.40 and its 200-day moving average price is $85.55. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14. Sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Jim Wassil sold 8,000 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the sale, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at $11,351,794.37. This represents a 4.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the transaction, the director now owns 7,175 shares of the company's stock, valued at $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,250 shares of company stock valued at $3,170,738 over the last three months. Corporate insiders own 3.10% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.